Search

NovoSeven: mode of action and use in acquired haemophilia.

This is a very good review on the use and mechanism of action of rFVIIa in acquired hemophilia. It reviews the physiological coagulation pathway and the central role of factor VII and tissue factor, and the changes which occur in hemophiliac patients. It also reviews the pathogenesis of acquired hemophilia and the results of using […]

Continuous infusion of coagulation factor products.

This is an interesting review on the use of continuous infusion of coagulation factor products over the last 11 years. It concludes that effects were favorable in comparison to intermittent bolus infusions. It suggests that continuous infusion has the advantage of maintaining a therapeutic level of the factor, and is associated with decrease in factor […]

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage.

This article reports 2 patients with severe thrombocytopenia and severe hemorrhage which did not respond to standard therapy and platelet transfusion, but responded quickly to administration of a single dose of rFVIIa. The first patient had Waldenstoms macroglobulinemia and immune thrombocytopenia, and the second one had acute lymphoblastic leukemia. No adverse effects for rFVIIa were […]

Successful use of recombinant factor VIIa for hemostasis during total knee replacement in a severe hemophiliac with high-titer factor VIII inhibitor.

This is another case report of a successful use of rFVIIa in covering knee replacement surgery in a patient with severe hemophilia A and high-titer inhibitor. rFVIIa was given at a dose of 85 u/kg at 2-hourly interval initially, increasing the interval between infusions every 48 hours. Effective hemostasis was achieved. The authors recommend administering […]